- Dosing of first subject in clinical trial by Pfizer triggers $5 million payment to Sosei Heptares
- Clinical development candidate is an oral, small molecule modulator of an undisclosed G protein-coupled receptor (GPCR) target
- Eighth GPCR-targeted drug candidate to enter clinical development originating from Sosei Heptares' StaR® technology/SBDD platform
PR Newswire
TOKYO and CAMBRIDGE, England, Sept. 28, 2020